BIOV Bioventus Inc. Class A Common Stock (MM)

First CRO to Offer GLP-Compliant Assay Services Using BioVeris' M-SERIES GAITHERSBURG, Md. and SALT LAKE CITY, July 19 /PRNewswire-FirstCall/ -- BioVeris Corporation (NASDAQ:BIOV) and Tandem Laboratories, a leading contract research organization (CRO) providing bioanalytical and immunoanalytical testing to the pharmaceutical industry, announced today that Tandem is the first CRO to offer Good Laboratory Practices (GLP) compliant assay services using BioVeris' products. Tandem acquired the BioVeris M-SERIES(R) Analyzer, reagents and BioVerification training to expand their offering of premiere assay technologies for biotechnology and pharmaceutical customers. Tandem already offers traditional ELISA assay services and wanted to add new methods that offered greater sensitivity, dynamic range and drug tolerance for GLP- compliant immunogenicity testing. Tandem's Vice President and General Manager of the Biomarker and Immunoanalytical Division, Ira DuBey, said, "We chose BioVeris' assay platform to complement our other methodologies for its advantages in assay performance, especially in pharmacokinetic and immunogenicity assays. Today, many more of our clients ask for BioVeris' ECL detection for their assays, and Tandem Laboratories is focused on delivering the highest quality testing coupled with customized service to our clients." BioVeris' Chief Executive Officer, Samuel Wohlstadter, stated, "We are pleased that Tandem Laboratories is the first CRO to adopt the M-SERIES platform for bioanalytical testing. We welcome Tandem as an experienced and well trained company that can support life science customers." BioVeris and Tandem believe that immunogenicity testing will become a large percentage of pharmaceutical drug development tests with the increased number of biotech products on the market. A paper issued by pharmaceutical and Food and Drug Administration experts in the Journal of Immunological Methods (volume 289, pages 1-16, 2004) illustrated many of the advantages of BioVeris' ECL technology compared to other methods available for immunogenicity testing. About Tandem Labs Tandem Labs is a privately held company with a 25-year history of applying scientific knowledge and technology to solutions in the life sciences. Since 1992, Tandem Labs has applied mass spectrometry and more recently immunoanalytical expertise in support of new drug development for the pharmaceutical and biopharmaceutical industries. This specialization has resulted in the emergence of Tandem Labs as a leading bioanalytical CRO. Tandem Labs offers rapid method development of LC/MS/MS and GC/MS/MS assays to support clinical and pre-clinical studies adhering to GLP. Hundreds of GLP proprietary methods have been validated including multi-analyte assays and those with concentration requirements in the low pg/mL range. Tandem Labs' discovery team specializes in rapid development, abbreviated validations, and high-throughput analysis of non-GLP samples. Tandem Labs' Biomarker and Immunoanalytical Division provides method development, validation, and sample analysis for novel and esoteric biomarkers as well as the analysis of biotherapeutics and antibodies. Further information about Tandem Labs is available at http://www.tandemlabs.com/. About BioVeris Corporation BioVeris Corporation is a global integrated health care company developing proprietary technologies in diagnostics and vaccinology. The Company is dedicated to the development and commercialization of innovative products and services for healthcare providers, their patients and their communities. BioVeris is headquartered in Gaithersburg, Maryland. Further information about BioVeris is available at http://www.bioveris.com/. This press release contains forward-looking statements within the meaning of the federal securities laws that relate to future events or BioVeris' future performance. All statements in this press release that are not historical facts, including any statements about the arrangement with Tandem Labs, market size and growth, and the utility or effectiveness of BioVeris' technology and products or Tandem Labs' services are hereby identified as "forward-looking statements." The words "may," "should," "will," "expect," "could," "anticipate," "believe," "estimate," "plan," "intend" and similar expressions have been used to identify certain of the forward-looking statements. In this press release, BioVeris has based these forward-looking statements on management's current expectations, estimates and projections and they are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements should, therefore, be considered in light of various important factors, including changes in general economic, business and industry conditions. The foregoing sets forth some, but not all, of the factors that could impact upon BioVeris' ability to achieve results described in any forward-looking statements. A more complete description of the risks applicable to BioVeris is provided in the Company's filings with the Securities and Exchange Commission (SEC) available at the SEC's web site at http://www.sec.gov/. Investors are cautioned not to place undue reliance on these forward-looking statements. Investors also should understand that it is not possible to predict or identify all risk factors and that neither this list nor the factors identified in BioVeris' SEC filings should be considered a complete statement of all potential risks and uncertainties. BioVeris has no obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this press release. DATASOURCE: BioVeris Corporation CONTACT: Jean Pineault, M.S. Vice President, Sales & Marketing of Tandem Laboratories and General Manager of Tandem Laboratories-New Jersey, +1-609-228-0201, , or Ira S. DuBey, M.S., M.B.A., Vice President and General Manager, Biomarker and Immunoanalytical Division, of Tandem Laboratories, +1-609-434-0044, ; George Migausky of BioVeris Corporation, +1-301-869-9800, ext. 2013; or Investors: Jonathan Fassberg of The Trout Group, +1-212-477-9007, ext. 16, or Media: Paul Caminiti or Andrew Cole of Citigate Sard Verbinnen, +1-212-687-8080, all for BioVeris Corporation Web site: http://www.bioveris.com/ http://www.tandemlabs.com/

Copyright